{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:48:11Z","timestamp":1792446491904,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s12325-022-02379-9","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T12:13:07Z","timestamp":1671019987000},"page":"869-886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week\u00a012 from the PSoHO Study in a Real-World Setting"],"prefix":"10.1007","volume":"40","author":[{"given":"Charles","family":"Lynde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia-Tatjana","family":"Maul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Fabbrocini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Brnabic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Holzk\u00e4mper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"2379_CR1","first-page":"370","volume":"23","author":"W Malatestinic","year":"2017","unstructured":"Malatestinic W, Nordstrom B, Wu JJ, et al. Characteristics and medication use of psoriasis patients who may or may not qualify for randomized controlled trials. J Manag Care Spec Pharm. 2017;23:370\u201381.","journal-title":"J Manag Care Spec Pharm"},{"key":"2379_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jdv.15878","volume":"34","author":"M Masson Regnault","year":"2020","unstructured":"Masson Regnault M, Casta\u00f1eda-Sanabria J, Diep Tran MHT, et al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2020;34:293\u2013300.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2379_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2012.26","volume":"2","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2: e54.","journal-title":"Nutr Diabetes"},{"key":"2379_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02324-4","author":"JE Ferguson","year":"2022","unstructured":"Ferguson JE, Seger EW, White J, et al. Racial\/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: a systematic review. Arch Dermatol Res. 2022. https:\/\/doi.org\/10.1007\/s00403-022-02324-4.","journal-title":"Arch Dermatol Res"},{"key":"2379_CR5","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21:1690.","journal-title":"Int J Mol Sci"},{"key":"2379_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/14656566.2019.1583207","volume":"20","author":"A Chiricozzi","year":"2019","unstructured":"Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019;20:863\u201372.","journal-title":"Expert Opin Pharmacother"},{"key":"2379_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jaad.2009.11.012","volume":"63","author":"M Lebwohl","year":"2010","unstructured":"Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol. 2010;63:571\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"2379_CR8","first-page":"320","volume":"179","author":"KA Papp","year":"2018","unstructured":"Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018;179:320\u20138.","journal-title":"Br J Dermatol"},{"key":"2379_CR9","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.13611","volume":"30","author":"A Menter","year":"2016","unstructured":"Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30:1148\u201358.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2379_CR10","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665\u201374.","journal-title":"Lancet"},{"key":"2379_CR11","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3711","volume":"101","author":"CP Hern\u00e1ndez-Fern\u00e1ndez","year":"2021","unstructured":"Hern\u00e1ndez-Fern\u00e1ndez CP, Carretero G, Rivera R, et al. Effect of sex in systemic psoriasis therapy: differences in prescription, effectiveness and safety in the BIOBADADERM prospective cohort. Acta Derm Venereol. 2021;101: adv00354.","journal-title":"Acta Derm Venereol"},{"key":"2379_CR12","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/bjd.20387","volume":"185","author":"JT Maul","year":"2021","unstructured":"Maul JT, Augustin M, Sorbe C, et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol. 2021;185:1160\u20138.","journal-title":"Br J Dermatol"},{"key":"2379_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s13555-021-00679-6","volume":"12","author":"JJ Crowley","year":"2022","unstructured":"Crowley JJ, Langley RG, Gordon KB, et al. Efficacy of risankizumab versus secukinumab in patients with moderate-to-severe psoriasis: subgroup analysis from the IMMerge study. Dermatol Ther. 2022;12:561\u201375.","journal-title":"Dermatol Ther"},{"key":"2379_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator\u2013controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405\u201317.","journal-title":"J Am Acad Dermatol"},{"key":"2379_CR15","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675\u201384.","journal-title":"Lancet"},{"key":"2379_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40257-017-0328-3","volume":"19","author":"M Amin","year":"2018","unstructured":"Amin M, No DJ, Egeberg A, et al. Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say? Am J Clin Dermatol. 2018;19:1\u201313.","journal-title":"Am J Clin Dermatol"},{"key":"2379_CR17","doi-asserted-by":"crossref","unstructured":"Pinter A, Puig L, Sch\u00e4kel K, et al. Comparative effectiveness of biologics in clinical practice: week\u00a012 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):2087\u20132100.","DOI":"10.1111\/jdv.18376"},{"key":"2379_CR18","doi-asserted-by":"crossref","unstructured":"Guillet C, Seeli C, Nina M, et al. The impact of gender and sex in psoriasis: what to be aware of when treating women with psoriasis. Int J Womens Dermatol. 2022;8(2):e010.","DOI":"10.1097\/JW9.0000000000000010"},{"key":"2379_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17738","volume":"181","author":"A Mourad","year":"2019","unstructured":"Mourad A, Straube S, Armijo-Olivo S, et al. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181:450\u20138.","journal-title":"Br J Dermatol"},{"key":"2379_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","volume":"22","author":"T Torres","year":"2021","unstructured":"Torres T, Puig L, Vender R, et al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22:567\u201379.","journal-title":"Am J Clin Dermatol"},{"key":"2379_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41:917\u201325.","journal-title":"Clin Drug Investig"},{"key":"2379_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244620","volume":"15","author":"Y-C Chen","year":"2021","unstructured":"Chen Y-C, Huang Y-T, Yang C-C, et al. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: an analysis of 75 patients in Taiwan. PLoS\u00a0One. 2021;15: e0244620.","journal-title":"PLoS\u00a0One"},{"key":"2379_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/JID.2015.378","volume":"136","author":"J Kim","year":"2016","unstructured":"Kim J, Oh C-H, Jeon J, et al. Molecular phenotyping small (Asian) versus large (Western) plaque psoriasis shows common activation of IL-17 pathway genes but different regulatory gene sets. J Investig Dermatol. 2016;136:161\u201372.","journal-title":"J Investig Dermatol"},{"key":"2379_CR24","first-page":"866","volume":"10","author":"SK Shah","year":"2011","unstructured":"Shah SK, Arthur A, Yang YC, et al. A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept. J Drugs Dermatol. 2011;10:866\u201372.","journal-title":"J Drugs Dermatol"},{"key":"2379_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.814938","volume":"8","author":"D Zhang","year":"2022","unstructured":"Zhang D, Qiu J, Liao X, et al. Comparison of efficacy of anti-interleukin-17 in the treatment of psoriasis between caucasians and Asians: a systematic review and meta-analysis. Front Med (Lausanne). 2022;8: 814938.","journal-title":"Front Med (Lausanne)"},{"key":"2379_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/ijd.14429","volume":"58","author":"T Lunder","year":"2019","unstructured":"Lunder T, Zorko MS, Kolar NK, et al. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol. 2019;58:631\u201341.","journal-title":"Int J Dermatol"},{"key":"2379_CR27","doi-asserted-by":"crossref","first-page":"204062231984375","DOI":"10.1177\/2040622319843756","volume":"10","author":"T-Y Ger","year":"2019","unstructured":"Ger T-Y, Huang Y-H, Hui RC, et al. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Therap Adv Chronic Dis. 2019;10:2040622319843756.","journal-title":"Therap Adv Chronic Dis"},{"key":"2379_CR28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjd.13343","volume":"172","author":"R Gniadecki","year":"2015","unstructured":"Gniadecki R, Bang B, Bryld LE, et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172:244\u201352.","journal-title":"Br J Dermatol"},{"key":"2379_CR29","unstructured":"European Medicines Agency. Psoriasis Study of Health Outcomes\u2014an international observational study of 3 year health outcomes in the biologic treatment of moderate to severe plaque psoriasis. In: (Pharmacovigilance ENoCfPa, ed). https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=25115: EUPAS24207. 2018. Accessed 31 Aug 2022."},{"key":"2379_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/10543406.2017.1289953","volume":"27","author":"AJ Zagar","year":"2017","unstructured":"Zagar AJ, Kadziola Z, Lipkovich I, et al. Evaluating different strategies for estimating treatment effects in observational studies. J Biopharm Stat. 2017;27:535\u201353.","journal-title":"J Biopharm Stat"},{"key":"2379_CR31","doi-asserted-by":"crossref","unstructured":"Zagar A, Kadziola Z, Lipkovich I, et al. Evaluating bias control strategies in observational studies using frequentist model averaging. J Biopharmaceutic Stat. 2022:32(2):247\u201376.","DOI":"10.1080\/10543406.2021.1998095"},{"key":"2379_CR32","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/bjd.19701","volume":"184","author":"T Graier","year":"2021","unstructured":"Graier T, Salmhofer W, Jonak C, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol. 2021;184:1094\u2013105.","journal-title":"Br J Dermatol"},{"key":"2379_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/1346-8138.14943","volume":"46","author":"M Kishimoto","year":"2019","unstructured":"Kishimoto M, Komine M, Kamiya K, et al. Drug survival of apremilast in a real-world setting. J Dermatol. 2019;46:615\u20137.","journal-title":"J Dermatol"},{"key":"2379_CR34","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Armstrong AW, Langley RG, et al. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. J Dermatol Treat. 2021;33(4):2317\u201324..","DOI":"10.1080\/09546634.2021.1959504"},{"key":"2379_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40257-017-0332-7","volume":"19","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Alexis AF. Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial\/ethnic groups. Am J Clin Dermatol. 2018;19:405\u201323.","journal-title":"Am J Clin Dermatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02379-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02379-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02379-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T07:23:47Z","timestamp":1678087427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02379-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2379"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02379-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article was revised due to update in Table 1.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}